Articles > Popular publications > PR Newswire press releases > July-September 1995 > Wednesday, September 6

Article: MEMORY EFFECTS IN HUMANS FROM CORTEX'S AMPALEX(TM); SAFETY TRIAL REVEALS IMPROVED MEMORY PERFORMANCE IN HEALTHY, YOUNG VOLUNTEERS

Article from:
PR Newswire
Article date:
September 6, 1995
Copyright

IRVINE, Calif., Sept. 6 /PRNewswire/ -- Cortex Pharmaceuticals, Inc. (Nasdaq: CORX) today announced that analysis of psychometric data from a Phase I study of CX516 (AMPALEX(TM)) in healthy young volunteers revealed apparent positive effects on memory performance. The results provide the first suggestion of the types of effects that can be expected from positive modulation of AMPA receptor function in the human brain.

The double-blind study, for which safety results were announced in February, was conducted in Berlin under the supervision of Dr. Werner Herrmann, a Professor at the Free University of Berlin and a leading expert on the clinical evaluation of central ... 







Read all of this article with a FREE trial
















Related newspaper, magazine, and journal articles:









  




 

    

 
 
   
 


   
  
  Article: CORTEX ANNOUNCES RESULTS FROM SECOND PHASE I TRIAL; ...

  
  PR Newswire; 
  January 25, 1996 ;  
  
  
 
  700+ words
... ... continued progress of the AMPALEX clinical studies ... Operating Officer of Cortex. "AMPALEX appears to be safe and ... testing procedures. AMPALEX is one of a family of ... AMPAKINES(TM) that Cortex is developing for the ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Enrollment Begins in Phase I/IIa Trial of Cortex's ...

  
  PR Newswire; 
  February 14, 1997 ;  
  
  
 
  700+ words
... ... 14 /PRNewswire/ -- Cortex Pharmaceuticals, Inc ... trial with CX516 ("AMPALEX(TM)") in patients ... In animal studies, AMPALEX has been shown to increase ... hippocampus and the cerebral cortex -- areas of the brain ... oral administrations of AMPALEX are safe and well tolerated ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: CORTEX BEGINS PHASE I TRIALS WITH AMPALEX

  
  PR Newswire; 
  October 21, 1994 ;  
  
  
 
  700+ words
... ... 21 /PRNewswire/ -- Cortex Pharmaceuticals Inc ... pharmacokinetic study of AMPALEX(TM), its lead compound ... executive officer of Cortex. "Our clinical approach ... knowledge of the safety of AMPALEX in humans. This will ... clinical studies." Cortex's AMPAKINE(TM) technology ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: CORTEX PHARMACEUTICALS COMPLETES PHASE I TRIAL OF ...

  
  PR Newswire; 
  February 1, 1995 ;  
  
  
 
  700+ words
... ... PRNewswire/ -- Cortex Pharmaceuticals Inc ... human safety study of AMPALEX(TM) (CX516 ... executive officer of Cortex. "Analysis of the ... has indicated that AMPALEX is safe and well ... clinical trials of AMPALEX subsequent to the ... pharmaceutical company. Cortex's AMPAKINE technology ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: CORTEX ANNOUNCES FIRST QUARTER FISCAL 1995 RESULTS; PHASE ...

  
  PR Newswire; 
  November 11, 1994 ;  
  
  
 
  700+ words
... ... Nov. 11 /PRNewswire/ -- Cortex Pharmaceuticals Inc. (Nasdaq ... corresponding prior year period. Cortex is developing a new generation ... the lead AMPAKINE compound, AMPALEX(TM), was initiated in late ... said Alan A. Steigrod, Cortex president and chief executive ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: KAROLINSKA STUDY FINDS AMPALEX(TM) SAFE AND WELL-TOLERATED ...

  
  PR Newswire; 
  June 19, 1996 ;  
  
  
 
  700+ words
... ... controlled human studies with AMPALEX(TM) (CX516). Cortex is developing AMPALEX for the potential treatment ... Vincent Simmon, Ph.D., Cortex President and Chief Executive ... This study confirms that AMPALEX is safe and well-tolerated ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: Cortex Licenses Ampakine Rights to Organon for ...

  
  PR Newswire; 
  January 13, 1999 ;  
  
  
 
  700+ words
... ... not have the disease. Cortex's Ampalex(R) (CX516) is currently ... Researchers evaluating Cortex's compounds noted that ... experiments performed by Cortex and its collaborators ... preliminary evidence that Ampalex may have a beneficial ... 







   
 




  




 

    

 
 
   
 


   
  
  Article: EXPERIMENTAL COMPOUND FROM CORTEX PHARMACEUTICALS, INC. ...

  
  PR Newswire; 
  June 6, 1996 ;  
  
  
 
  700+ words
... ... that a new study by Cortex collaborators at ... UCI) showed that AMPALEX(TM) (CX516 ... investigators at Cortex and the University ... examine the effects of AMPALEX and other AMPAKINEs ... administration of AMPALEX. Cortex, located in Irvine ... 







   
 

























 



 





 






Newsweek
Harper's Magazine
The Washington Post
Chicago Tribune
Crain's Chicago Business
PRNewswire
Pediatric News
The Nation
Advertising Age
The Economist (US)
A FREE trial gives you access to over 80 million articles!
Access over 6,500 publications with a FREE trial!


  



Find articles, research, and archives